Literature DB >> 20503059

Prognostic value of (18)F-fluorodeoxyglucose positron emission tomography in patients with extrahepatic bile duct cancer.

Koji Kitamura1, Etsuro Hatano, Tatsuya Higashi, Satoru Seo, Yuji Nakamoto, Masato Narita, Kojiro Taura, Kentaro Yasuchika, Takashi Nitta, Kenya Yamanaka, Ryuichiro Doi, Iwao Ikai, Shinji Uemoto.   

Abstract

BACKGROUND: (18)F-fluorodeoxyglucose positron emission tomography (FDG-PET) is used in the differential diagnosis and staging of extrahepatic bile duct cancer (EBDC), but its prognostic value has not been fully elucidated. In this study, we investigated the prognostic value of FDG-PET in EBDC patients.
METHODS: The study included 73 consecutive patients with EBDC, of whom 48 underwent surgical resection for EBDC. The effects of clinicopathological factors including the standardized uptake value (SUV) of the primary lesion and lymph node metastasis detected by FDG-PET (PET-N) on overall survival were evaluated.
RESULTS: In all 73 patients, multivariate analysis showed that surgical resection (risk ratio 2.5, 95% confidence interval [CI] 1.17-5.35, P = 0.018) and the SUV (2.0, 1.07-3.91, P = 0.030) were independent predictors of survival. In the 48 patients who underwent surgical resection, multivariate analysis revealed that perineural invasion (risk ratio 3.2, 95% CI 1.28-7.93, P = 0.012), pathologic lymph node metastasis (3.4, 1.27-9.17, P = 0.015), and PET-N (4.0, 1.10-15.25, P = 0.036) were independent predictors of overall survival. In the 25 patients without surgical resection, the SUV showed a significant relationship with overall survival (P = 0.014).
CONCLUSION: Our data suggest that the SUV of the primary lesion is a useful prognostic factor in patients with EBDC, and the prognosis for patients with PET-N remains very poor despite surgical resection.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20503059     DOI: 10.1007/s00534-010-0293-1

Source DB:  PubMed          Journal:  J Hepatobiliary Pancreat Sci        ISSN: 1868-6974            Impact factor:   7.027


  12 in total

1.  Prognostic and predictive value of metabolic tumor volume on (18)F-FDG PET/CT in advanced biliary tract cancer treated with gemcitabine/oxaliplatin with or without erlotinib.

Authors:  Moon Ki Choi; Joon Young Choi; Jeeyun Lee; Jin Seok Heo; Seong Ho Choi; Dong Wook Choi; Kyu Taek Lee; Jong Kyun Lee; Kwang Hyuck Lee; Joon Oh Park; Young Suk Park; Ho Yeong Lim
Journal:  Med Oncol       Date:  2014-06-10       Impact factor: 3.064

2.  Perineural invasion in extrahepatic cholangiocarcinoma: prognostic impact and treatment strategies.

Authors:  Yoshiaki Murakami; Kenichiro Uemura; Takeshi Sudo; Yasushi Hashimoto; Naru Kondo; Naoya Nakagawa; Takeshi Muto; Hayato Sasaki; Kazuhide Urabe; Taijiro Sueda
Journal:  J Gastrointest Surg       Date:  2013-08       Impact factor: 3.452

3.  Metabolic Characteristics of Advanced Biliary Tract Cancer Using 18F-Fluorodeoxyglucose Positron Emission Tomography and Their Clinical Implications.

Authors:  Kyoung-Min Cho; Do-Youn Oh; Tae-Yong Kim; Kyung Hun Lee; Sae-Won Han; Seock-Ah Im; Tae-You Kim; Yung-Jue Bang
Journal:  Oncologist       Date:  2015-06-22

4.  The Role of F-18 FDG PET/CT in Intrahepatic Cholangiocarcinoma.

Authors:  Yeongjoo Lee; Ie Ryung Yoo; Sun Ha Boo; Hyoungwoo Kim; Hye Lim Park; Joo Hyun O
Journal:  Nucl Med Mol Imaging       Date:  2016-08-06

5.  Prognostic significance of standardized uptake value on preoperative ¹⁸F-FDG PET/CT in patients with ampullary adenocarcinoma.

Authors:  Hye Jin Choi; Chang Moo Kang; Kwanhyeong Jo; Woo Jung Lee; Jae-Hoon Lee; Young Hoon Ryu; Jong Doo Lee
Journal:  Eur J Nucl Med Mol Imaging       Date:  2014-09-13       Impact factor: 9.236

6.  A single-center analysis of the survival benefits of adjuvant gemcitabine chemotherapy for biliary tract cancer.

Authors:  Kenya Yamanaka; Etsuro Hatano; Masashi Kanai; Shiro Tanaka; Keiichi Yamamoto; Masato Narita; Hiromitsu Nagata; Takamichi Ishii; Takahumi Machimoto; Kojiro Taura; Shinji Uemoto
Journal:  Int J Clin Oncol       Date:  2013-06-14       Impact factor: 3.402

7.  Nerve Growth Factor Expression Is Not Associated with Perineural Invasion in Extrahepatic Cholangiocarcinoma.

Authors:  Kazuhide Urabe; Yoshiaki Murakami; Naru Kondo; Kenichiro Uemura; Yasushi Hashimoto; Naoya Nakagawa; Hayato Sasaki; Eiso Hiyama; Shinya Takahashi; Taijiro Sueda
Journal:  Dig Dis Sci       Date:  2015-11-07       Impact factor: 3.199

8.  Diagnostic accuracy of fluorine-18-fluorodeoxyglucose positron emission tomography in the evaluation of the primary tumor in patients with cholangiocarcinoma: a meta-analysis.

Authors:  Salvatore Annunziata; Carmelo Caldarella; Daniele Antonio Pizzuto; Federica Galiandro; Ramin Sadeghi; Luca Giovanella; Giorgio Treglia
Journal:  Biomed Res Int       Date:  2014-05-13       Impact factor: 3.411

9.  Prognostic Value of SUVmax Measured by Fluorine-18 Fluorodeoxyglucose Positron Emission Tomography with Computed Tomography in Patients with Gallbladder Cancer.

Authors:  Jae Pil Hwang; Ilhan Lim; Im Ii Na; Eung Ho Cho; Byung Ii Kim; Chang Woon Choi; Sang Moo Lim
Journal:  Nucl Med Mol Imaging       Date:  2013-12-06

10.  Tubular adenoma of the common bile duct with uptake in 18F-FDG PET: A case report.

Authors:  Kentaro Hokonohara; Takehiro Noda; Hisanori Hatano; Akihiro Takata; Masashi Hirota; Kazuteru Oshima; Tsukasa Tanida; Takamichi Komori; Shunji Morita; Hiroshi Imamura; Takashi Iwazawa; Kenzo Akagi; Shiro Hayashi; Masami Inada; Shiro Adachi; Keizo Dono
Journal:  Mol Clin Oncol       Date:  2015-11-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.